Natera (NTRA) 주식 개요
진단 회사인 Natera는 전 세계적으로 분자 검사 서비스를 개발하고 상용화하는 일을 하고 있습니다. 자세히 보기
강점
위험 분석
우리의 위험 점검에서 NTRA에 대한 위험이 감지되지 않았습니다.
NTRA Community Fair Values
Create NarrativeSee what 56 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Natera, Inc. 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$328.93 |
| 52주 최고가 | US$343.18 |
| 52주 최저가 | US$157.43 |
| 베타 | 1.53 |
| 1개월 변동 | 6.13% |
| 3개월 변동 | 49.44% |
| 1년 변동 | 91.06% |
| 3년 변동 | 544.20% |
| 5년 변동 | 174.84% |
| IPO 이후 변동 | 1,346.48% |
최근 뉴스 및 업데이트
Recent updates
내러티브 업데이트 • Sep 03
NTRA: Elevated Expectations Around MRD Adoption Will Pressure 2026 Catalyst Payoff
The analyst price target for Natera has been revised higher from $206.81 to $280.00 as analysts incorporate Q2 report takeaways, stronger expectations around Signatera performance, oncology and MRD volume trends, and improving profitability into their models. Analyst Commentary Recent Street research on Natera clusters around a constructive view of the core oncology and minimal residual disease, or MRD, opportunity, while also highlighting valuation sensitivity and execution risk.Seeking Alpha • Aug 26
Natera: The Growth May Not Justify Current Levels
Summary Signatera is Natera’s strongest asset, supported by strong clinical performance, broad Medicare coverage, growing adoption, and multiple recent regulatory milestones. Natera has exceptional growth, with revenue up 38% and processed tests up 22% year-over-year, while oncology and MRD volumes grew approximately 57%. Despite strong fundamentals, Natera’s valuation appears excessive, with virtually all valuation metrics being at a much higher level than the sector median. Read the full article on Seeking Alpha
내러티브 업데이트 • Aug 18
NTRA: Guideline MRD Tailwinds Will Drive Future Oncology Volume Upside
Natera's analyst price target has been raised from $330 to $375, with analysts pointing to stronger modeled revenue growth supported by continued execution in oncology and Women's Health, record and guideline supported Signatera volumes, and updated models after Q2 results that still factor in a higher discount rate and a higher future P/E multiple, alongside somewhat lower projected profit margins. Analyst Commentary Recent Street research around Natera centers on sustained execution in oncology and minimal residual disease, or MRD, testing, with Signatera frequently highlighted as a key driver.내러티브 업데이트 • Aug 04
NTRA: Guideline And Regulatory MRD Tailwinds Will Drive Long-Term Upside Potential
The analyst price target for Natera has been raised by $20, from $310 to $330. Analysts cite larger addressable markets, ongoing volume trends, and a series of recent guideline wins and regulatory approvals that support slightly higher revenue growth, profit margins, and a higher future P/E in updated models.
내러티브 업데이트 • Jul 20
NTRA: Guideline And Regulatory Tailwinds Will Support Balanced 2026 MRD Outlook
The updated analyst price target for Natera moves from $260.05 to $282.14, reflecting analysts' use of higher group multiples and ongoing expectations around large addressable markets, volume trends, and guideline and regulatory catalysts for Signatera in their revised models. Analyst Commentary Recent research on Natera shows a cluster of higher price targets and mostly positive ratings, with a few more cautious voices tempering expectations.내러티브 업데이트 • Jul 06
NTRA: Guideline And Regulatory MRD Tailwinds Will Support Measured Long-Term Trajectory
Natera's updated fair value estimate edges up to $310, supported by analysts' higher price targets across the diagnostics sector and their view that trends in procedure volumes, capital spending, guideline support for Signatera, and MRD adoption continue to favor the company's testing portfolio. Analyst Commentary Recent research coverage on Natera has been active, with several bullish analysts revisiting their assumptions around the company’s testing portfolio, guideline traction for Signatera, and minimal residual disease, or MRD, adoption.내러티브 업데이트 • Jun 22
NTRA: MRD Guideline Tailwinds Will Support 2026 Catalyst Heavy Outlook
The analyst price target for Natera has edged down slightly to $260.05 from about $260.89, as analysts factor in updated assumptions for revenue growth, profit margins, and future P/E. They also highlight the potential uptake of Signatera following new NCCN guideline support and a continued focus on minimal residual disease testing adoption and reimbursement.분석 기사 • Jun 20
Natera (NTRA) Stock Could Be 11.3% Undervalued After Prospera Transplant Data
Natera (NTRA) is back in focus after new transplant data at the 2026 American Transplant Congress linked its Prospera test to future adverse outcomes even when biopsies are negative, alongside fresh collaboration headlines. See our latest analysis for Natera. The recent Prospera data and new transplant collaborations have arrived alongside a strong run in Natera’s shares, with a 30-day share price return of 12.93% and a 1-year total shareholder return of 34.65%. The 3-year total shareholder...내러티브 업데이트 • Jun 05
NTRA: MRD Leadership And FDA Approval Will Support Long-Term Trajectory
Analysts have made a modest adjustment to their outlook on Natera, with the average price target moving slightly and recent commentary highlighting the company’s position in molecular residual disease testing. Firms have set a range of targets from $245 to $260 as they balance growth reinvestment with expectations for future operating leverage.내러티브 업데이트 • May 22
NTRA: Molecular Residual Disease Leadership Will Support 2026 Catalyst Heavy Outlook
Natera's updated analyst price target has edged higher to about $261 from roughly $259, as analysts factor in a slightly higher fair value, a modestly adjusted discount rate and revenue growth outlook, and a stronger expected profit margin alongside a lower future P/E assumption. Analyst Commentary Recent Street research on Natera shows active recalibration of price targets, with several bullish revisions offset by a smaller number of trims.분석 기사 • May 13
Analysts Have Made A Financial Statement On Natera, Inc.'s (NASDAQ:NTRA) First-Quarter Report
As you might know, Natera, Inc. ( NASDAQ:NTRA ) recently reported its quarterly numbers. Results overall were mixed...내러티브 업데이트 • May 05
NTRA: MRD Leadership And New Genomic Offering Will Support Long-Term Trajectory
Analysts have kept their $300 price target on Natera unchanged, while slightly adjusting assumptions for discount rate, revenue growth, profit margins and future P/E after a mix of recent research that includes both modest target cuts and higher targets tied to updated models, guidance and a generally constructive view on the stock. Analyst Commentary Recent research paints a generally constructive picture of how Wall Street views Natera, with multiple bullish analysts fine tuning their models around updated guidance, P/E assumptions and profitability paths.내러티브 업데이트 • Apr 20
NTRA: Oncology Execution And 2026 Catalysts Will Shape Fairly Valued Outlook
Analysts have trimmed the blended price target for Natera by about $2 to reflect updated models that incorporate slightly higher discount rates, revised revenue growth and profit margin assumptions, and a lower future P/E multiple, while still indicating constructive views from recent research coverage. Analyst Commentary Recent research on Natera presents a mix of supportive long term views and valuation recalibrations, with several firms updating models after quarterly results and competitive developments in genetic testing.내러티브 업데이트 • Apr 05
NTRA: Molecular Residual Disease Leadership Will Drive Bullish Long Term Outlook
Analysts made a modest trim to the blended price target on Natera to about $259, reflecting slightly lower modeled revenue growth and profit margins. This adjustment comes even as several firms recently raised individual targets into the $215 to $300 range after updating their views on the company following Q4 results and new coverage initiations.내러티브 업데이트 • Mar 22
NTRA: Molecular Residual Disease Leadership And Genomics Launch Will Shape Future Outlook
The analyst fair value estimate for Natera has been adjusted modestly higher from $257.20 to $260.65, reflecting updated models that incorporate recent Street price target revisions and assumptions for revenue growth, profit margins, and future P/E multiples. Analyst Commentary Street research around Natera has centered on how the company executes on its current guidance, maintains its position in key testing markets, and justifies premium valuation multiples through future growth and margin delivery.내러티브 업데이트 • Mar 07
NTRA: Elevated Oncology And 2026 Catalyst Hopes Will Likely Cap Future Upside
The updated analyst price target for Natera edges higher to a fair value estimate of $208.44 from $194.59, reflecting recent Street research where several firms lifted their targets following Q4 results, improved gross margin commentary, and expectations for a catalyst rich 2026. Analyst Commentary Recent Street research on Natera points to a mixed backdrop, with a cluster of higher price targets sitting well above the updated fair value estimate of $208.44, but also some signs of restraint as models are refreshed after Q4 results and initial 2026 guidance.내러티브 업데이트 • Feb 21
NTRA: MRD Leadership And Broad Test Portfolio Will Support Long-Term Trajectory
Narrative Update on Natera Analysts have refreshed their views on Natera with price targets now reaching up to $300. This is supported by expectations for solid sector results, confidence in the company’s position across women's and organ health, and its growing role in the molecular residual disease market.내러티브 업데이트 • Feb 07
NTRA: Molecular Residual Disease Leadership And FDA Progress Will Shape Future Outlook
Analysts have raised their fair value estimate for Natera to about $257 from roughly $235, citing higher assumed revenue growth, improved profit margins, and Street research that highlights the company as an established diagnostics player with a strong position in molecular residual disease, along with multiple recent price target increases up to $300. Analyst Commentary Recent Street research has been broadly constructive on Natera, with several bullish analysts lifting their price targets and emphasizing the company’s role in diagnostics and molecular residual disease.내러티브 업데이트 • Jan 24
NTRA: Expanding MRD Adoption And New Data Will Support Long-Term Trajectory
Analysts have lifted their Natera price targets into a US$220 to US$300 range, citing recent earnings beats, raised estimates, and what they describe as strong fundamentals and a long growth runway across diagnostics and molecular residual disease testing. Analyst Commentary Recent Street research points to a cluster of higher Natera price targets, with several bullish analysts citing what they view as strong execution in diagnostics and molecular residual disease testing.내러티브 업데이트 • Jan 09
NTRA: Expanding MRD Adoption And Trials Will Support Long-Term Revenue Trajectory
Analysts have raised their fair value estimate for Natera to $300 from $285, citing a series of higher Street price targets and ongoing enthusiasm around the company's position in women's and organ health and the molecular residual disease market. Analyst Commentary Bullish analysts have been resetting their expectations higher, with a series of price target revisions in recent months that cluster in the US$210 to US$300 range.내러티브 업데이트 • Dec 26
NTRA: Expanding Oncology Diagnostics Will Drive Stronger Long-Term Revenue Trajectory
The analyst fair value estimate for Natera has been raised to $285 from $268, as analysts factor in stronger anticipated revenue growth and sustained momentum in key diagnostics franchises, reflected in a series of higher Street price targets. Analyst Commentary Bullish analysts have recently raised their price targets on Natera across the board, citing stronger than expected execution and a robust outlook for revenue growth.내러티브 업데이트 • Dec 12
NTRA: Elevated Expectations Around Oncology Expansion Will Likely Constrain Future Share Returns
Natera's analyst fair value estimate has been raised sharply from approximately $115 to about $195 per share, reflecting analysts' higher long term revenue growth assumptions and confidence following a series of recent price target increases across the Street. Analyst Commentary Recent Street research has been predominantly constructive on Natera, with multiple firms lifting price targets into the $200 to $280 range and reiterating positive ratings.내러티브 업데이트 • Nov 27
NTRA: Recent Clinical Results And Competitive Position Will Influence Future Outlook
Natera's analyst price target has been raised to $234.68 from $222.58. Analysts cite ongoing strong revenue performance, increased growth expectations, and recent research milestones as the primary drivers for the upward revision.주주 수익률
| NTRA | US Biotechs | US 시장 | |
|---|---|---|---|
| 7D | 0.2% | -5.2% | -0.9% |
| 1Y | 91.1% | 38.0% | 13.9% |
수익률 대 산업: NTRA은 지난 1년 동안 38%의 수익을 기록한 US Biotechs 산업보다 더 좋은 성과를 냈습니다.
수익률 대 시장: NTRA은 지난 1년 동안 13.9%를 기록한 US 시장보다 더 좋은 성과를 냈습니다.
주가 변동성
| NTRA volatility | |
|---|---|
| NTRA Average Weekly Movement | 8.0% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 15.3% |
| 10% least volatile stocks in US Market | 2.9% |
안정적인 주가: NTRA는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: NTRA의 주간 변동성(8%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 2003 | 6,138 | Steve Chapman | www.natera.com |
는 진단 회사로 전 세계에서 분자 검사 서비스를 개발 및 상용화하고 있습니다. 암 진단을 받은 환자의 MRD 평가, 조기 재발 모니터링, 치료 반응 평가를 위한 개인 맞춤형 ctDNA 혈액 검사 시그나테라, 혈액 기반 대장암 MRD 검사 래티튜드, 조직 기반 종합 게놈 프로파일링 검사 알테라, 유전성 암 선별 검사 엠파워를 제공합니다. 또한 비침습 산전 검사 파노라마(Panorama), 보인자 선별 검사 호라이즌(Horizon), 21가지 단일 유전자 유전 질환을 선별하는 단일 유전자 NIPT 또는 sgNIPT인 태아 포커스(Fetal Focus), 25가지 단일 유전자 질환을 선별하는 단일 유전자 NIPT인 비스타라(Vistara)를 제공하고 있습니다.
Natera, Inc. 기초 지표 요약
| NTRA 기초 통계 | |
|---|---|
| 시가총액 | US$47.41b |
| 순이익 (TTM) | -US$192.35m |
| 매출 (TTM) | US$2.71b |
17.5x
주가매출비율(P/S)-246.5x
주가수익비율(P/E)NTRA는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| NTRA 손익계산서 (TTM) | |
|---|---|
| 매출 | US$2.71b |
| 매출원가 | US$941.25m |
| 총이익 | US$1.77b |
| 기타 비용 | US$1.96b |
| 순이익 | -US$192.35m |
최근 보고된 실적
Jun 30, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | -1.33 |
| 총이익률 | 65.23% |
| 순이익률 | -7.11% |
| 부채/자본 비율 | 4.4% |
NTRA의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/09/14 05:25 |
| 종가 | 2026/09/11 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Natera, Inc.는 36명의 분석가가 다루고 있습니다. 이 중 23명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Catherine Ramsey Schulte | Baird |
| Robert Bamberger | Baird |
| Luke Sergott | Barclays |